NASDAQ · CAPR
Healthcare · Biotechnology
$7.24
Up+$0.86 (+13.48%)
Updated Nov 3, 2026, 2:30 AM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CAPR
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
CAPR closed at $7.24 after 21 trading sessions, down 6.94% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $6.88 | $7.455 | $6.67 | $7.24 | 5.04M |
| Oct 30, 2026 | $6.5831 | $6.64 | $6.14 | $6.38 | 3.36M |
| Oct 29, 2026 | $6.24 | $6.93 | $6.24 | $6.63 | 3.33M |
| Oct 28, 2026 | $6.00 | $6.405 | $5.9001 | $6.23 | 2.98M |
| Oct 27, 2026 | $5.79 | $6.31 | $5.67 | $6.10 | 3.48M |
| Oct 26, 2026 | $5.91 | $5.95 | $5.685 | $5.74 | 1.55M |
| Oct 23, 2026 | $6.03 | $6.08 | $5.80 | $5.93 | 1.46M |
| Oct 22, 2026 | $5.83 | $6.355 | $5.80 | $6.13 | 2.76M |
| Oct 21, 2026 | $6.60 | $6.75 | $5.79 | $5.88 | 3.42M |
| Oct 20, 2026 | $6.53 | $6.8345 | $6.47 | $6.61 | 2.05M |
| Oct 19, 2026 | $6.82 | $6.925 | $6.54 | $6.65 | 1.91M |
| Oct 16, 2026 | $7.21 | $7.25 | $6.68 | $6.71 | 1.95M |
| Oct 15, 2026 | $6.64 | $7.33 | $6.64 | $7.27 | 3.36M |
| Oct 14, 2026 | $6.76 | $6.885 | $6.47 | $6.59 | 2.52M |
| Oct 13, 2026 | $7.32 | $7.3999 | $6.87 | $6.88 | 2.69M |
| Oct 12, 2026 | $7.79 | $7.81 | $7.445 | $7.47 | 1.46M |
| Oct 9, 2026 | $8.01 | $8.05 | $7.69 | $7.83 | 1.7M |
| Oct 8, 2026 | $7.89 | $8.17 | $7.80 | $8.01 | 2.52M |
| Oct 7, 2026 | $7.59 | $8.27 | $7.4605 | $8.10 | 2.89M |
| Oct 6, 2026 | $7.75 | $7.89 | $7.46 | $7.75 | 3.13M |
| Oct 5, 2026 | $8.75 | $8.80 | $7.371 | $7.78 | 6.77M |
The latest Smart Investors Daily articles mentioning CAPR.
Company
Market Activity
Research & News
CAPR research
Company profile and research snapshot.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 14, 2026 | B. Riley Securities | Buy | — |
| Sep 1, 2026 | Piper Sandler | Overweight | — |
| Aug 14, 2026 | Cantor Fitzgerald | Overweight | — |
| Jul 31, 2026 | Jones Trading | Hold | — |
| Jul 30, 2026 | Piper Sandler | Neutral | — |
No generated briefing is available yet.
Yahoo · Oct 21, 2026
The FDA is slated to decide on approving Capricor’s Deramiocel for the treatment of Duchenne muscular dystrophy by November 22.
SeekingAlpha · Oct 13, 2026
2026-10-13. The following slide deck was published by Capricor Therapeutics, Inc.
Yahoo · Oct 7, 2026
Craig McDonald said on Wednesday that in patients in the HOPE-3 trial with weakened hearts, Deramiocel treatment produced “essentially complete stabilization” over a year.
Yahoo · Oct 7, 2026
Capricor Therapeutics (NASDAQ:CAPR) presented updated clinical data for deramiocel in Duchenne muscular dystrophy, or DMD, including two-year open-label extension results from its Phase III HOPE-3 study and additional statistical analyses submitted to the U.S. Food and Drug Administration. Company
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CAPR.
